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Introduction
============

Acute coronary syndrome (ACS) remains a deadly and costly condition. One of the most common ways it is assessed is through a cardiac stress test. In this test, the patient's heart is stressed using either exercise or medications to increase its oxygen demand. The patient's heart is then assessed for inducible myocardial ischemia (a precursor to ACS) using some form of diagnostic imaging \[[@REF1]-[@REF3]\]. Accordingly, cardiac stress tests require sophisticated equipment and trained personnel to perform and interpret. This limits the test's availability and affordability, leading to frequent hospitalization for patients with possible ACS. A different paradigm is needed to diagnose ACS.

One potential solution would be to utilize bloodstream biomarkers in the place of imaging studies to detect inducible myocardial ischemia. Multiple studies have attempted to determine whether there are dynamic biomarker correlates of inducible myocardial ischemia. B-type natriuretic peptide (BNP) is released by the myocardium in response to ventricular wall stretch. It has been hypothesized that BNP would also be released in myocardial ischemia, given that induced myocardial ischemia is associated with abnormal ventricular wall motion in the affected area. Prior individual studies examining changes in BNP as a predictor of stress test-induced myocardial ischemia were underpowered to make definitive conclusions and have findings that contradict one another \[[@REF4]-[@REF12]\]. Others have also studied the BNP precursor, N-terminal pro-B-type natriuretic peptide (NT-proBNP), which has similar characteristics as a biomarker and similarly found contradictory results \[[@REF10], [@REF13]-[@REF15]\].

If clinicians could reliably use changes in bloodstream biomarkers following stress to detect myocardial ischemia, the need for highly trained personnel and sophisticated equipment for an imaging study could be precluded. Using "stress-delta" biomarkers in such a manner could have multiple advantages, including increased cost-effectiveness, efficiency, availability, and reproducibility. The goal of this systematic review and meta-analysis is to determine the utility of stress-delta BNP levels and its precursor, NT-proBNP, for detecting inducible myocardial ischemia during cardiac stress testing.

Materials and methods
=====================

This systematic review is reported in accordance with the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) statement \[[@REF16]\].

Eligibility criteria

Studies were eligible if they examined the changes in BNP or its precursor, NT-proBNP, before and after a stress test to assess myocardial ischemia in patients with known or suspected to have coronary artery disease. We excluded studies that examined these biomarkers in patients with systolic heart failure and in studies using them as prognostic rather than diagnostic markers. We also excluded studies that failed to exclude patients with congestive heart failure and studies that used pharmacological stress testing.

Information sources

We searched the following electronic databases: PubMed, Excerpta Medica database (EMBASE), Web of Science, Cumulative Index of Nursing and Allied Health Literature (CINAHL), and Ovid. In addition, we searched the references of the included articles manually for further studies that would meet the eligibility criteria. When necessary, we also contacted authors of eligible studies for data not reported.

Search

The initial search comprised the Medical Subject Headings (MeSH) terms "myocardial ischemia," "brain natriuretic peptide," "BNP," "diagnostic test," and related entry terms. The complete search strategy used for the PubMed and EMBASE databases is shown in Table [1](#TAB1){ref-type="table"}. We did not use limits for language and date when conducting the searches.

###### PubMed Search Strategy

  -------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Search   Query
  \#4      Search (\#1 AND \#2 AND \#3)
  \#3      Search (\"Natriuretic Peptide, Brain\"\[Mesh\] OR \"Peptide, Brain Natriuretic\"\[All Fields\] OR \"Brain Natriuretic Peptide\"\[All Fields\] OR \"BNP-32\"\[All Fields\] OR \"BNP 32\"\[All Fields\] OR \"Nesiritide\"\[All Fields\] OR \"B-Type Natriuretic Peptide\"\[All Fields\] OR \"Natriuretic Peptide, OR B-Type\"\[All Fields\] OR \"BNP Gene Product\"\[All Fields\] OR \"Type-B Natriuretic Peptide\"\[All Fields\] OR \"Natriuretic Peptide, Type-B\"\[All Fields\] OR \"Type B Natriuretic Peptide\"\[All Fields\] OR \"Natriuretic Peptide Type-B\"\[All Fields\] OR \"Natriuretic Peptide Type B\"\[All Fields\] OR \"Natriuretic Factor-32\"\[All Fields\] OR \"Natriuretic Factor 32\"\[All Fields\] OR \"Brain Natriuretic Peptide-32\"\[All Fields\] OR \"Brain Natriuretic Peptide 32\"\[All Fields\] OR \"Natriuretic Peptide-32, Brain\"\[All Fields\] OR \"Peptide-32, Brain Natriuretic\"\[All Fields\] OR \"Ventricular Natriuretic Peptide, B-type\"\[All Fields\] OR \"Ventricular Natriuretic Peptide, B type\"\[All Fields\] OR \"Natrecor\"\[All Fields\] OR \"Basic natriuretic peptide\"\[All Fields\] OR \"B-type Natriuretic Peptide (BNP) blood test\"\[All Fields\] OR \"B-type Natriuretic Peptide blood test\"\[All Fields\] OR \"B-type Natriuretic Peptide (BNP)\"\[All Fields\] OR \"BNP\"\[All Fields\] OR \"BNP blood test\"\[All Fields\])
  \#2      Search (\"Diagnostic Test Accuracy\"\[All Fields\] OR \"Diagnostic Study\"\[All Fields\] OR \"Sensitivity and Specificity\"\[Mesh\] OR \"Specificity and Sensitivity\"\[All Fields\] OR \"Sensitivity\"\[All Fields\] OR \"Specificity\"\[All Fields\])
  \#1      Search (\"Myocardial Ischemia\"\[Mesh\] OR \"Ischemia, Myocardial\"\[All Fields\] OR \"Ischemias, Myocardial\"\[All Fields\] OR \"Myocardial Ischemias\"\[All Fields\] OR \"Ischemic Heart Disease\"\[All Fields\] OR \"Heart Disease, Ischemic\"\[All Fields\] OR \"Disease, Ischemic Heart\"\[All Fields\] OR \"Diseases, Ischemic Heart\"\[All Fields\] OR \"Heart Diseases, Ischemic\"\[All Fields\] OR \"Ischemic Heart Diseases\"\[All Fields\] OR \"Coronary Artery Disease\"\[Mesh\] OR \"Artery Disease, Coronary\"\[All Fields\] OR \"Artery Diseases, Coronary\"\[All Fields\] OR \"Coronary Artery Diseases\"\[All Fields\] OR \"Disease, Coronary Artery\"\[All Fields\] OR \"Diseases, Coronary Artery\"\[All Fields\] OR \"Coronary Arteriosclerosis\"\[All Fields\] OR \"Arterioscleroses, Coronary\"\[All Fields\] OR \"Coronary Arterioscleroses\"\[All Fields\] OR \"Atherosclerosis, Coronary\"\[All Fields\] OR \"Atheroscleroses, Coronary\"\[All Fields\] OR \"Coronary Atheroscleroses\"\[All Fields\] OR \"Coronary Atherosclerosis\"\[All Fields\] OR \"Arteriosclerosis, Coronary\"\[All Fields\])
  -------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Study selection

Two reviewers (SK and AH) independently evaluated titles and abstracts of the retrieved articles. Abstracts that did not provide enough information regarding the eligibility criteria were kept for full-text evaluation. Reviewers independently evaluated full-text articles and determined study eligibility. Disagreements were resolved by consensus, and if any disagreement persisted, a third reviewer's opinion (ATL) was sought.

Risk of bias

The risk of bias was evaluated by ranking each study according to standard factors using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool. Bias assessment considered each study's representativeness, reference standard acceptability, the delay between the index and reference standard, avoidance of partial or differential verification, avoidance of incorporation of index test into reference standard, blinding, the relevance of results, reporting of intermediate/indeterminate results, and explanation of withdrawals.

Data extraction

Two reviewers (SK and AH) independently conducted the data extraction and disagreements were resolved by the third reviewer (ATL). General characteristics of the studies were collected, such as study design, study settings, population description, age, and data collection time range. Most importantly, the required data for this study, including baseline and ending BNP or NT-Pro-BNP, disease prevalence, type of stress, and times that outcome was measured, were also collected.

Data analysis

Due to a wide skew in BNP and NT-Pro-BNP distributions in the studies that met the eligibility criteria, as well as the wide variation in methods among the studies, a meta-analysis was only performed on the studies reporting mean and a variability measure for both outcomes. Thus, to summarize all studies, we also qualitatively report studies' median and mean values ordered by sample sizes.

Meta-analysis models were built for BNP and NT-Pro-BNP delta values (difference) between pre- and post-stress testing comparing normal and ischemic patients. Heterogeneity across the studies was examined through the Cochrane\'s Q (considering p-values lower than 0.1 to indicators of heterogeneity), H and I2statistics \[[@REF17]\]. High I2 values indicate high heterogeneity with a proposed categorization of 25% (low), 45% (moderate), and 75% (high) \[[@REF17]\]. In our study, we adopted the interpretation of the fixed-effect model because our main goal is to obtain the true-effect of BNP and NT-Pro-BNP along the different population sizes reported. Sensitivity analyses were conducted by including different subsets of articles based on their quality rank, which allowed us to test the robustness of our results. A forest plot was constructed to depict these results. All analyses were performed through the R language software (R-Project, version 3.1.0, 2016), specifically through the meta package and metafor package \[[@REF18]\].

Results
=======

Study selection

A total of 1,253 records were identified after searching through the various databases. Sixty-eight full-text articles were assessed for eligibility and 46 were excluded, leaving 22 articles that met the inclusion criteria. After further evaluation, only 15 studies contained unique data and were included in our synthesis. Of the 15 studies, six studies reported results in means and nine studies reported results in medians and were included in this systematic review (Figure [1](#FIG1){ref-type="fig"}).

![Study selection flowchart\
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Study characteristics

The population characteristics of these studies can be seen in Table [2](#TAB2){ref-type="table"}. The mean age of participants ranged from 57 to 66 years old. The prevalence of ischemia in the studies ranged between 16.7% and 78%. The number of patients in each study ranged between 44 and 274. Only studies with exercise stress testing were included.

###### Characteristics of Included Studies

\*studies examining both BNP and NT-proBNP

BNP: B-type natriuretic peptide; CAD: coronary artery disease; MPI: myocardial perfusion imaging; NT-proBNP: N-terminal pro-B-type natriuretic peptide; SPECT: single-photon emission computed tomography

  ---------------------------------- ------ ------------------------------------ ----------------------------------------------------------------------------------------------- ---------- --------- ----------------------------------------- ----- ------------------------
  Study                              Year   Setting                              Study Population                                                                                Mean Age   Men (%)   Type of Stress                            N     Prevalence of ischemia
  BNP                                                                                                                                                                                                                                                  
  Lee et al. \[[@REF7]\]             2014   University Hospital of Basel         Consecutive patients with suspected CAD referred for stress testing                             62         68%       Bicycle exercise with SPECT               274   37.6%
  Staub et al. \[[@REF8]\]           2006   University Hospital of Basel         Consecutive patients referred for CAD evaluation by bicycle ergometry MPI SPECT                 63         70%       Bicycle exercise MPI SPECT                256   49.6%
  Zaid et al. \[[@REF4]\]            2006   Bnai-Zion Medical Center             Consecutive patients referred for chest pain evaluation                                         59         67%       Exercise with nuclear perfusion imaging   203   52%
  Moller et al. \[[@REF9]\]          2008   Mayo Clinic, Rochester               Patients referred for evaluation of angina or exertional dyspnea                                65         55%       Bicycle exercise echo                     140   46%
  Paraskevaidis et al. \[[@REF5]\]   2011   Outpatient clinic                    Consecutive patients with chest pain                                                            58.7       80%       Treadmill exercise                        100   78%
  \*Foote et al. \[[@REF10]\]        2004   Dartmouth Hitchcock Medical Center   Consecutive patients with CAD referred for MPI SPECT                                            58.8       84%       Exercise with MPI SPECT                   74    54%
  Marumoto et al. \[[@REF6]\]        1995   \-                                   35 patients with angiographically proven angina and 35 angiographically normal patients         61.1       67%       Exercise stress test with SPECT           70    50%
  Bergeron et al. \[[@REF11]\]       2006   \-                                   Patients referred for clinically indicated exercise echo                                        66         82%       Treadmill exercise with echo              60    31.7%
  Win et al. \[[@REF12]\]            2005   \-                                   Patients undergoing treadmill exercise for evaluation of chest pain or screening for ischemia   57.2       68%       Treadmill exercise with SPECT             60    16.7%
  NT-Pro BNP                                                                                                                                                                                                                                           
  Staub et al. \[[@REF13]\]          2005   University Hospital Basel            Consecutive patients referred for CAD evaluation                                                63         70%       Bicycle exercise with SPECT               260   49.6%
  Vanzetto et al. \[[@REF14]\]       2007   University Hospital of Grenoble      Patients with known stable CAD referred for exercise MPI                                        61         88%       Bicycle exercise MPI                      102   55.9%
  Van der Zee et al. \[[@REF15]\]    2009   \-                                   Consecutive patients referred for evaluation of inducible ischemia                              61         64%       Bicycle exercise with SPECT               101   36.6%
  Başkurt et al. \[[@REF19]\]        2011   Outpatient clinic                    Patients with a history of exercise-induced angina or atypical angina                           57         63%       Exercise stress test                      96    50%
  \*Foote et al. \[[@REF12]\]        2004   Dartmouth Hitchcock Medical Center   Consecutive patients with CAD referred for MPI SPECT                                            58.8       84%       Exercise with MPI SPECT                   74    54%
  Chatha et al. \[[@REF20]\]         2006   Rapid access chest pain clinic       All patients with chest pain from rapid access chest pain clinic                                58         46%       Exercise stress test                      59    23.7%
  Zhu et al. \[[@REF21]\]            2010   Zhongshan Hospital                   Patients with chest pain and suspected CAD                                                      \-         \-        Treadmill exercise                        44    56.8%
  ---------------------------------- ------ ------------------------------------ ----------------------------------------------------------------------------------------------- ---------- --------- ----------------------------------------- ----- ------------------------

Out of the total 15 studies included, eight studies examined BNP, six examined NT-proBNP, and one examined both. Table [3](#TAB3){ref-type="table"} depicts the data in order of sample size for studies examining BNP with median and mean stress-deltas, respectively. Eight of the nine BNP studies demonstrated a higher stress-delta value in patients with ischemic stress tests than in patients with normal stress tests. These studies represent 1,177 of the 1,237 patients (95%) with stress-delta BNP.

###### Stress-delta BNP/NT-proBNP Studies (ng/L)

"Delta-delta" refers to the stress-delta BNP for patients with ischemia on stress imaging, minus the stress-delta BNP for patients with normal stress imaging.

BNP: B-type natriuretic peptide; IQR: interquartile range; N: number; NT-proBNP: N-terminal pro-B-type natriuretic peptide; SD: standard deviation

  ---------------------------------- ------------------- ---------------------- ---------------------- -------------------- --------- ----- --------------------- --------------------- ------------------ ------- -----
  Authors                            Ischemic Patients                          Normal Patients        Delta-Delta          Total N                                                                                
                                     N                   Baseline               Post                   Delta                          N     Baseline              Post                  Delta                       
  Median BNP (IQR)                                                                                                                                                                                                  
  Lee et al. \[[@REF7]\]             103                 105.7 (57.1 - 176.9)   130.5 (74.3 - 260.9)   24.8                           171   56.6 (30.4 - 94.3)    72.4 (44.4 - 116.3)   15.8               9       274
  Staub et al. \[[@REF8]\]           127                 70.8 (34.8 - 146.5)    87.5 (42.2 - 173.6)    16.7                           129   38.1 (19.6 - 81.4)    52.2 (24.7 - 102.3)   14.1               2.6     256
  Moller et al. \[[@REF9]\]          65                  19 (8.8 - 34.6)        29.6 (17.6 - 46.5)     10.6                           75    12.1 (4.6 - 26.9)     16.3 (7.1 - 34.1)     4.2                6.4     140
  Foote et al. \[[@REF10]\]          40                  40.5 (24 - 54)         77 -                   36.5 (15 - 49.5)               34    16.5 (9.5 - 30.5)     24 -                  7.5 (3.5 - 17.5)   29      74
  Win et al. \[[@REF12]\]            10                  13.4 (9.5 - 30.6)      26.7 (19.3 - 61.5)     13.2                           50    15.05 (7 - 37.7)      34.7 (14.9 - 67.6)    19.65              -6.45   60
  Bergeron et al. \[[@REF11]\]       19                  24 (10 - 69)           50 (30 - 94)           26                             41    15 (8.1 - 24)         29 (13 - 40)          14                 12      60
  Mean BNP (SD)                                                                                                                                                                                                     
  Zaid et al. \[[@REF4]\]            106                 117 (+/- 292)          149 (+/- 356)          32                             97    50 (+/- 66)           67 (+/- 88)           17                 15      203
  Paraskevaidis et al. \[[@REF5]\]   78                  21.8 (+/- 15.3)        69.9 (+/- 63.2)        48.1                           22    14.2 (+/- 17.0)       38.2 (+/- 51.1)       24                 24.1    100
  Marumoto et al. \[[@REF6]\]        35                  2.8 (+/- 0.8)          6.9 (+/- 2.6)          4.1                            35    2.7 (+/- 0.7)         2.9 (+/- 1.0)         0.2                3.9     70
  Median Pro-BNP (IQR)                                                                                                                                                                                              
  Staub et al. \[[@REF13]\]          129                 155 (84 - 360)         169 (90 - 391)         14                             131   91 (43 - 228)         100 (50 - 244)        9                  5       260
  Vanzetto et al. \[[@REF14]\]       57                  182 (97 - 265)         212 (104 - 315)        30                             45    85 (44 - 164)         99 (50 - 179)         14                 16      102
  Van der Zee et al. \[[@REF15]\]    37                  184 (57 - 386)         214 -                  30 (7 - 45)                    64    74 (21 - 255)         89 -                  15 (4 - 46)        15      101
  Foote et al. \[[@REF10]\]          40                  120.5 (76 - 158)       135 -                  14.5 (10.5 - 19.5)             34    53.5 (28 - 74)        57.5 -                4 (0.5 - 9.5)      10.5    74
  Mean Pro-BNP (SD)                                                                                                                                                                                                 
  Başkurt et al. \[[@REF19]\]        48                  175.1 (+/- 392.3)      201.5 (+/- 461.6)      26.4                           48    92.2 (+/- 130.5)      102.5 (+/- 139.2)     10.3               16.1    96
  Chatha et al. \[[@REF20]\]         14                  71.4 (+/- 41.2)        76.8 (+/- 44.0)        5.4                            45    54 (+/- 61.2)         60.1 (+/- 69.0)       6.1                -0.7    59
  Zhu et al. \[[@REF21]\]            25                  187.97 (+/- 166.29)    197 (+/- 178.82)       9.03                           19    107.27 (+/- 105.15)   117.911 (+/- 93.34)   10.64              -1.61   44
  ---------------------------------- ------------------- ---------------------- ---------------------- -------------------- --------- ----- --------------------- --------------------- ------------------ ------- -----

Table [3](#TAB3){ref-type="table"} also demonstrates the data from studies examining NT-proBNP with median and mean stress-deltas, respectively. Five of the seven studies demonstrated that patients with ischemic stress tests had higher stress-delta values compared to normal patients. These studies represent 633 of the 736 patients (86%) with stress-delta NT-proBNP calculated.

Van der Zee et al. \[[@REF15]\] assessed the change of NT-proBNP at time-points greater than two hours post-stress. The study appears to show similar results at the time-points greater than two hours. In fact, this study shows higher stress-delta values at time-points greater than two hours compared to immediately post-stress.

Risk of bias

Our bias assessment results are demonstrated in Figure [2](#FIG2){ref-type="fig"}. Four studies (Paraskevaidis et al., Lee et al., Staub et al., and Staub et al.) addressed all of the 11 characteristics evaluated \[[@REF5], [@REF7]-[@REF8], [@REF13]\]. The remaining 11 studies did not address whether the reference standard results were blinded and five of those studies also did not mention if the index test results were blinded. Studies by Başkurt et al. and Chatha et al. used an exercise treadmill test alone without imaging as a reference standard for the evaluation of coronary artery disease \[[@REF19]-[@REF20]\]. Foote et al. and Başkurt et al. were also at risk for partial verification \[[@REF10], [@REF19]\]. Başkurt et al. only evaluated with angiography if the exercise stress test was positive \[[@REF19]\]. Foote et al. only used an exercise treadmill in healthy volunteers while using an exercise treadmill, as well as imaging, in the population with suspected coronary artery disease \[[@REF10]\].

![Assessment of risk\
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Meta-analysis

The standardized difference between normal and ischemic patients' stress-delta BNP values was -0.39 (95% confidence interval (CI): -0.61; -0.17) in a fixed-effect model and -0.73 (95% CI: -1.72; 0.28) in the random-effects model (Figure [3](#FIG3){ref-type="fig"}). The model revealed high heterogeneity (I2 = 94%, Q test P = 0.001). Sensitivity analysis showed that excluding the study by Marumoto et al. \[[@REF6]\] would produce a significant improvement to the model, reaching almost no heterogeneity (I2 = 0%, Q test P = 0.001), and a decrease in the estimated pooled standardized mean difference to -0.13 (CI 95%: -0.37; 0.11). Overall, the results correspond to a homogeneous model and show that ischemic patients had a slightly higher BNP delta than normal patients, although the difference was not statistically significant.

![Meta-analysis of studies reporting mean values\
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For NT-proBNP, the meta-analysis model showed no significant difference between the stress-delta test for ischemic and normal patients (standardized mean difference (SMD): -0.02, 95% confidence interval (CI): -0.31, 0.28). The NT-proBNP delta values for ischemic patients were similar to the normal patient group in a low heterogeneity fixed-effects model (Figure 11).

Discussion
==========

While some have questioned the utility of routine stress testing, it remains the guideline-recommended care for patients presenting with symptoms of the potential acute coronary syndrome \[[@REF22]-[@REF24]\]. Routine stress testing has further come into question in light of findings that coronary interventions in stable patients with positive stress tests do not prevent future acute myocardial infarction or death \[[@REF25]\]. The ability to utilize a bloodstream biomarker to reliably detect inducible myocardial ischemia could reduce the need for sophisticated equipment and highly trained personnel currently used for stress testing \[[@REF1]-[@REF3]\]. Since the imaging component of contemporary stress testing is not usually available 24 hours per day, the need for stress testing drives many of the hospitalizations for patients with symptoms of acute coronary syndrome. A biomarker-based stress test, therefore, could make ACS assessment more affordable and efficient since laboratory testing is routinely available continuously in most hospitals.

It has long been recognized that BNP is released by the myocardium in response to ventricular wall stretch \[[@REF26]\]. This has been observed in patients with chronic and acute-on-chronic congestive heart failure \[[@REF27]\]. It has, therefore, been hypothesized that BNP would also be released in the setting of myocardial ischemia, given the observation that induced myocardial ischemia is associated with abnormal ventricular wall motion activity \[[@REF26], [@REF28]\]. A prior meta-analysis examined whether a single, resting BNP, or NT-proBNP level can predict inducible myocardial ischemia on stress testing and found relatively high diagnostic test characteristics \[[@REF29]\].

Accordingly, we attempted to systematically review and synthesize the existing literature exploring the relationship of dynamic BNP release from induced myocardial ischemia occurring during stress testing by examining the stress-delta BNP levels. In our analysis, patients without inducible ischemia appeared to have lower baseline BNP and NT-proBNP values compared to patients with inducible ischemia by stress testing. Stress-delta BNP values were slightly higher in patients with inducible ischemia. However, we were unable to definitively identify a relationship between inducible ischemia and statistically different stress-delta BNP or NT-proBNP values after sensitivity analysis.

This systematic review and analysis have several strengths. We conducted a comprehensive search of various databases in addition to going through all citations of the included studies. We used standardized definitions of inclusion and exclusion criteria and trained abstractors with excellent agreement.

Qualitative analysis of the results suggests that there is not a strong relationship between median stress-delta BNP and inducible ischemia when the blood samples are drawn at peak exercise or immediately after stress testing. Thus, the timing of blood sampling may play a critical role in assessing the utility of any stress-delta biomarker paradigm.

We note some limitations to our systematic review. The study population of included papers appears to have a wide range of pretest probability of disease among subjects, and there was a wide range of prevalence of ischemia noted as well. There was a great deal of heterogeneity in the studies examined with regard to methods and results. There are many factors that can influence BNP levels, and although we eliminated studies that included patients with systolic heart failure, other causes of elevated baseline BNP that could skew results (such as valvular disorders, pulmonary hypertension, and left ventricular diastolic dysfunction) were not consistently controlled. There was variation in the BNP and NT-proBNP assays used. There was also no standardization of blood draw time points; some studies sampled during peak exercise while others were drawn within minutes after finishing. Further increase after stress may occur and thus requires further investigation. NT-proBNP has a longer half-life of two to three hours and has a higher baseline compared to BNP. Therefore, small absolute increases may be harder to detect \[[@REF30]\]. The study by Van Der Zee et al. examining changes in NT-proBNP over time after stress showed a peak change immediately at peak exercise, at the second peak at four hours in patients with ischemia, and at five hours in patients without ischemia \[[@REF15]\]. In addition, treadmill exercise might not be a significant enough stressor to induce myocardial ischemia or it might produce an ischemic state that is too short to create significant stress-delta changes. Finally, stress modalities for inducing myocardial ischemia may also affect the result. The pharmacologic stress test, such as dobutamine and dipyridamole, has not been widely studied and was excluded from our studies.

Conclusions
===========

In conclusion, a systematic review failed to reach a consensus on whether stress-delta BNP or NT-proBNP reliably elevates in response to myocardial ischemia caused by a cardiac stress test. Our meta-analysis of the available data showed no statistical difference; however, the type of data reported in the literature added limitations to the meta-analysis model. Further studies with larger sample sizes and with longer post-stress time sampling will be necessary to better determine their utility in the assessment of potential ACS patients.
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